Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split is to regain compliance with Nasdaq Listing Rule 5550(a)(2).
This action will reduce the outstanding common stock from approximately 4.77 million shares to approximately 1.59 million shares.
Reverse Stock Split
1 for 3 reverse stock split to maintain Nasdaq listing compliance.
Board and Shareholder Approval
Approved by the Board of Directors and shareholders of the Company.
Impact on Shares
Reduction of outstanding common stock to enhance shareholder value.
- The reverse split aims to enhance the visibility and credibility of Entero Therapeutics on the Nasdaq market.
- By consolidating shares, the company seeks to increase shareholder value and meet listing requirements.
The reverse stock split demonstrates Entero Therapeutics' commitment to maintaining its Nasdaq listing and enhancing shareholder value.